2002年美国批准的新活性物质(一) 被引量：4

暂未订购

导出

摘要美国FDA 2002年批准了89个新药,其中包括了26个新活陛物质,即17个新分子实体(NME,表1)与9个生物制品(表2).此外,2002年FDA还在已上市的医药产品中,批准增加了172个新适应证.

作者黄东临

机构地区国家经贸委医药工业信息中心站

出处《世界临床药物》 CAS 2003年第3期185-188,共4页 World Clinical Drug

关键词 2002年美国新活性物质 FDA ZETIA Benicar ABILIFY Xyrem

参考文献4

1钟小仕,陈辉,覃丹平,肖笑,刘岩.依普利酮对大鼠单侧输尿管梗阻模型肾间质纤维化的影响[J].中国中西医结合肾病杂志,2011,12(2):108-111. 被引量：1
2韩超,韩广甸.依普利酮合成路线图解[J].中国医药工业杂志,2010,41(4):309-312. 被引量：4
3杨路,华丹宇,杨良衍.依普利酮合成中有关物质的NMR研究[J].中国医药工业杂志,2010,41(12):922-925. 被引量：2
4江洪,胡丹.醛固酮受体阻断剂依普利酮的研究进展[J].世界临床药物,2004,25(1):19-22. 被引量：2

1黄杰雄.增殖细胞核抗原的研究进展[J].国外医学（生理病理科学与临床分册）,1994,14(1):9-11. 被引量：94
2Krum H,Nolly H,Workman D,et al.Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients[J].Hypertension,2002,40 (2):117-123.
3Funder JW.New biology of aldosterone,and experimental studies on the selective aldosterone blocker eplerenone[J].Am HeartJ,2002,144(suppl 5):S8-S11.
4Piepho RW.Overview of the angiotensin-converting-enzyme inhibitors[J].Am J Health-Syst Pharm,2000,57 (suppl 1):S3-S7.
5Ng JS,Wang PT,Baez JA,et al.Process for preparation of 7a-carboxyl-9,11-epoxy steroids and intermediates useful therein and a general process for the epoxidation of olefmic double bonds:WO,9721720[P].1999-02-24.(CA 1997,127:120750).
6Ng JS,Liu C,Anderson DK,et al.Process for preparation of 9,11-epoxy steroids and intermediates useful therein:WO,9825948[P].2000-5-17.(CA 1998,129:81885).
7王少仲,李建新,王磊,等.依普利酮的合成方法:中国,1310941[P].2007-04-18.(CA 2006,145:28162).
8Wuts PGM.Processes for preparing 7-carboxy substituted Steroids:US,7196208[P].2007-03-27.(CA 2004,140:391400).
9Pearlman BA,Padilla AG,Hach JT,et al.A new approach to the furan degradation problem involving ozonolysis of the trans-enedione and its use in a cost-effective synthesis of eplerenone[J].Org Lett,2006,8(10):2111-2113.
10Pearlman BA,Padilla AG,Havens JL,et al.Process to prepare eplerenone:US,7235655[P].2007-06-26.(CA 2003,139:307925).

1黄杰雄.增殖细胞核抗原的研究进展[J].国外医学（生理病理科学与临床分册）,1994,14(1):9-11. 被引量：94
2Krum H,Nolly H,Workman D,et al.Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients[J].Hypertension,2002,40 (2):117-123.
3Funder JW.New biology of aldosterone,and experimental studies on the selective aldosterone blocker eplerenone[J].Am HeartJ,2002,144(suppl 5):S8-S11.
4Piepho RW.Overview of the angiotensin-converting-enzyme inhibitors[J].Am J Health-Syst Pharm,2000,57 (suppl 1):S3-S7.
5Ng JS,Wang PT,Baez JA,et al.Process for preparation of 7a-carboxyl-9,11-epoxy steroids and intermediates useful therein and a general process for the epoxidation of olefmic double bonds:WO,9721720[P].1999-02-24.(CA 1997,127:120750).
6Ng JS,Liu C,Anderson DK,et al.Process for preparation of 9,11-epoxy steroids and intermediates useful therein:WO,9825948[P].2000-5-17.(CA 1998,129:81885).
7王少仲,李建新,王磊,等.依普利酮的合成方法:中国,1310941[P].2007-04-18.(CA 2006,145:28162).
8Wuts PGM.Processes for preparing 7-carboxy substituted Steroids:US,7196208[P].2007-03-27.(CA 2004,140:391400).
9Pearlman BA,Padilla AG,Hach JT,et al.A new approach to the furan degradation problem involving ozonolysis of the trans-enedione and its use in a cost-effective synthesis of eplerenone[J].Org Lett,2006,8(10):2111-2113.
10Pearlman BA,Padilla AG,Havens JL,et al.Process to prepare eplerenone:US,7235655[P].2007-06-26.(CA 2003,139:307925).

1韩超,韩广甸.依普利酮合成路线图解[J].中国医药工业杂志,2010,41(4):309-312. 被引量：4
2杨路,华丹宇,杨良衍.依普利酮合成中有关物质的NMR研究[J].中国医药工业杂志,2010,41(12):922-925. 被引量：2
3钟小仕,陈辉,覃丹平,肖笑,刘岩.依普利酮对大鼠单侧输尿管梗阻模型肾间质纤维化的影响[J].中国中西医结合肾病杂志,2011,12(2):108-111. 被引量：1
4江洪,胡丹.醛固酮受体阻断剂依普利酮的研究进展[J].世界临床药物,2004,25(1):19-22. 被引量：2

世界临床药物

2003年第3期

内容加载中请稍等...